Novartis to expand commitment to Neglected Tropical Diseases

Novartis to expand commitment to Neglected Tropical Diseases

The pharmaceutical company is joining the Global Chagas Disease Coalition to help improve access to diagnosis and treatment for people suffering from Chagas. Additionally, Novartis has announced the launch of a multinational study in people suffering from the Neglected Tropical Disease.

Chagas disease, also known as American trypanosomiasis, affects over a six million people worldwide.  The Neglected Tropical Disease is transmitted through the bite of a bug (Trypanosoma cruzi) and can lead to intestinal complications and chronic heart failures. The WHO estimates that Chagas disease causes approximately 12 000 deaths annually. Novartis, a member of SANTD, has recently joined the Global Chagas Disease Coalition to increase its commitment to the fight against Chagas. The company has also announced its commitment to launch a study to assess if people suffering from Chagas could benefit from a heart failure drug produced by the pharmaceutical company.

Follow this link to the press release published by Novartis.

Image Credit: Jim Gathany/CDC

Leave a Reply

Your email address will not be published.